Januvia and the pancreas
Merck's juggernaut diabetes drug Januvia now faces renewed scrutiny five years after an endocrinologist found that lab rats given the medicine were more susceptible to pancreatic cancer, according to a report in The New York Times.
After followup studies by the same doctor, Peter Butler, the Food and Drug Administration and the European Medicines Agency have begun investigations that could lead to new warnings on Whitehouse Station-based Merck's Januvia and other drugs in its class, according to The Times report.
In March, the FDA also said it was reviewing unpublished findings by a group of academic researchers tha...
Source: PharmaGossip - May 30, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Alzheimer's and Dementia News 251
This study is currently recruiting new participants.
_________________________________________________
Related Content
Test Your Memory for Alzheimer's (5 Best Tests)
What is the Difference Between Alzheimer’s and Dementia
Alzheimer's Communication Tip, No More Blah Blah Blah
How to Listen to an Alzheimer's Patient
Learning How to Communicate with Someone Suffering From Alzheimer's Disease
Alzheimer's World Bang Your Head Against the Wall
The Combination of Aricept and Namenda Helps Slow the Rate of Decline in Alzheimer's Patients
_________________________________________________
Dominantly Inherited Alzheimer Network...
Source: Alzheimer's Reading Room, The - April 20, 2013 Category: Dementia Authors: Bob DeMarco Source Type: blogs
Disturbing Study: Both Families of Incretin Drugs Appear to Cause Potentially Cancerous Changes in the Pancreas
Researchers just published a study in the journal Diabetes in which they autopsied the pancreases of 20 people with diabetes, 12 of whom were taking incretin drugs as well as those of 14 people without diabetes. Most had died of stroke or head injuries, leaving their pancreases in excellent condition. The researchers wanted to see if, in fact, as claimed, the incretin drugs--the drugs that raise the concentration of GLP-1 or mimic GLP-1--cause an increase in the beta cell mass. These drugs have been promoted with the promise that they do, that they regenerate the pancreas. This is one major reason doctors prescribe them ev...
Source: Diabetes Update - March 25, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
March Diabetes News Snippet Post
Here are all the news items posted in March: Jennysaid... People taking Byetta, Victoza, Januvia, and Onglyza had less heart failure than those not on these drugs. http://www.sciencedaily.com/releases/2013/03/130310164109.htmHowever, it is likely this is because Avandia and Actos CAUSE heart failure, rather than that these other drugs prevent it. People are rarely put on both families of drugs at once. It may also be because these GLP-1 related drugs are mostly prescribed to affluent, younger people with diabetes and good health insurance, while poorer people are put on the cheap sulfonylurea drugs which are now known to ...
Source: Diabetes Update - March 11, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
Pancreatitis Risks And A Pair Of Diabetes Drug
Yet another potentially worrisome sign for a pair of widely used diabetes drugs. A new study indicates that Merck’ Januvia and Bristol-Myers Squibb’s as Byetta can double the risk of developing pancreatitis, which is an inflammation of the pancreas that is linked to cancer and kidney failure. This is the same issue that has plagued both drugs over the past few years.
The study, which examined insurance records for more than 2,500 diabetics between February 2005 and December 2008, found that patients hospitalized with pancreatitis were twice as likely to be taking either of the drugs than a control group of Type...
Source: Pharmalot - February 26, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Bristol Myers Squibb Byetta Diabetes Eli Lilly Januvia Merck Novo Nordisk Victoza Source Type: blogs
Keeping the Pounds On: Causes of Unexplained Weight Loss
By Amy Campbell
Our society is obsessed with weight, if you haven't noticed. More than two thirds of US adults are overweight or obese, there are more diet books published than we can count, and, of course, we have the privilege of watching shows like The Biggest Loser to help keep us in line. And according to government statistics, more than 85% of people with Type 2 diabetes are overweight. So it stands to reason that much of the focus of managing Type 2 diabetes is based on reaching and staying at a healthy weight.
It's important to note that thin people can get diabetes too, and not just Type 1 diabetes. In a 2008 stud...
Source: Diabetes Self-Management - February 25, 2013 Category: Diabetes Authors: Amy Campbell Source Type: blogs
Another Dangerously Misinterpreted Study: Insulin Doesn't Raise Cancer & Heart Disese Risk--High Blood Sugars Do
A huge, long-term UK study appears to show that for people with Type 2 Diabetes injecting insulin raises the risk of both cancer and heart disease.The study is:Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 DiabetesCraig J. Currie et al. The Journal of Clinical Endocrinology & Metabolism February 1, 2013 vol. 98 no. 2 668-677The study examined the records of 84,622 people with Type 2 Diabetes treated with 5 different drug combinations. It concludes: " In people with T2DM, exogenous insulin therapy was associated with an increased risk of diab...
Source: Diabetes Update - February 21, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
Sunday Funnies: Diabetes Med Wars
In with the new, out with the old... Byetta vs. Victoza... Sometimes changing up diabetes meds can kind of feel like dealing with temperamental pets. Thanks to the talented Mike Durbin, who blogs at My Diabetic Heart and shared recently that h... (Source: Diabetes Mine)
Source: Diabetes Mine - February 10, 2013 Category: Endocrinology Authors: Amy Tenderich Source Type: blogs
New to Diabetes: What's Next? (Part 1)
By Amy Campbell
Back in October, I posted a piece called "Getting Started With Type 2 Diabetes." My intent with that was to provide you with an overview of what to do when you're told you have diabetes (or what to do if you've had diabetes for a while but perhaps hadn't been ready to manage it).
Now that we're in a new year, I thought it might be helpful to expand upon that piece a bit. As you and I well know, taking care of your diabetes can seem like a full-time job, and if this is all new to you, it can be a bit bewildering trying to sort it all out. So in the spirit of new beginnings, this week I'll share a couple mor...
Source: Diabetes Self-Management - January 7, 2013 Category: Diabetes Authors: Amy Campbell Source Type: blogs
And Along Came Tradjenta... Or, The Wacky World of Type 2 Drugs
The world of type 2 diabetes drugs is wacky indeed. While Amylin's long-acting version of Byetta - called Bydureon and predicted by many experts to become a blockbuster - is still held up at FDA, the agency approved a new oral drug earlier this mo... (Source: Diabetes Mine)
Source: Diabetes Mine - May 27, 2011 Category: Endocrinology Authors: Amy Tenderich Source Type: blogs
New drugs: Exenatide – an injectable diabetic agent and Denosumab – a monoclonal antibody for postmenopausal osteoporosis
Exanatide (Byetta):
the first injectable synthetic analogue of the incretin hormone glucagon-like peptide-1 (GLP-1)
note that the glyptins inhibit incretin breakdown and are thus incretin “enhancers” not “mimics”
PBS approved for type 2 diabetics as an addition to the combination of metformin and sulphonylurea to help lower HbA1c below 7% or as dual Rx for those who cannot tolerate metformin or a sulphonylurea.
dose:
is given bd s/c within 1 hour BEFORE meals starting at 5 mcg per dose which should be at least 6 hours apart
after 1 month, dose can be increased to 10mcg bd
main adverse effect...
Source: Oz E Medicine - emergency medicine in Australia - December 11, 2010 Category: Emergency Medicine Authors: Gary Tags: new drugs Source Type: blogs
Byetta Fallout Hits Novo Nordisk (That Pancreatitis Scare)
This morning Novo Nordisk announced that the FDA has scheduled an advisory committee meeting for its new Liraglutide once-daily GLP-1 drug, currently awaiting FDA approval. Believe it or not, this is huge news - with the potential to make or bre... (Source: Diabetes Mine)
Source: Diabetes Mine - September 5, 2008 Category: Endocrinology Authors: Amy Tenderich Source Type: blogs
Byetta Fallout Hits Novo Nordisk (That Pancreatitis Scare)
This morning Novo Nordisk announced that the FDA has scheduled an advisory committee meeting for its new Liraglutide once-daily GLP-1 drug, currently awaiting FDA approval. Believe it or not, this is huge news - with the potential to make or bre... (Source: Diabetes Mine)
Source: Diabetes Mine - September 5, 2008 Category: Endocrinology Authors: Amy Tenderich Source Type: blogs
